MWM
BPMC icon

Mascoma Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Mascoma Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-150
Closed -$14K – 114
2019
Q2 		$14K Buy
+150
New +$12.4K 0.01% 245

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Mascoma Wealth Management's BPMC Position: Q3 2019 in Review

Mascoma Wealth Management sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 150 shares — an estimated $14K sold.

Mascoma Wealth Management first reported a position in BPMC in Q2 2019 and held it in 1 quarter. The position peaked at $14K in Q2 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Mascoma Wealth Management reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
  • Mascoma Wealth Management sold 150 Blueprint Medicines shares in Q3 2019, an estimated $14K.
  • Mascoma Wealth Management first reported a position in Blueprint Medicines in Q2 2019 and held it in 1 quarter.
  • Mascoma Wealth Management's Blueprint Medicines position peaked at $14K in Q2 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Mascoma Wealth Management's 13F filing for Q3 2019, filed 21 Nov 2019.